BioCentury
ARTICLE | Clinical News

DB959: Phase Ib started

April 11, 2011 7:00 AM UTC

Dara BioSciences began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate 5, 20 and 100 mg oral DB959 once daily for 7 days in 24 patients. Dara licensed the compound from Bayer in 20...